VOYA Investment Management
ALLO icon

VOYA Investment Management’s Allogene Therapeutics ALLO Stock Holding History

VOYA Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.4K Sell
25,976
-876
-3% -$1.76K ﹤0.01% 2252
2025
Q4 		$36.8K Hold
26,852
– – ﹤0.01% 2361
2025
Q3 		$33.3K Sell
26,852
-15,671
-37% -$18.7K ﹤0.01% 2416
2025
Q2 		$48.1K Buy
42,523
+7,926
+23% +$10.5K ﹤0.01% 2608
2025
Q1 		$50.5K Sell
34,597
-3,210
-8% -$6.05K ﹤0.01% 2549
2024
Q4 		$80.5K Buy
37,807
+436
+1% +$1.07K ﹤0.01% 2622
2024
Q3 		$105K Buy
37,371
+1,501
+4% +$4K ﹤0.01% 2652
2024
Q2 		$83.6K Buy
35,870
+4,458
+14% +$13.2K ﹤0.01% 2710
2024
Q1 		$140K Sell
31,412
-6,935
-18% -$28.9K ﹤0.01% 2550
2023
Q4 		$123K Buy
38,347
+4,851
+14% +$13.8K ﹤0.01% 2707
2023
Q3 		$106K Buy
33,496
+1,249
+4% +$5.47K ﹤0.01% 2714
2023
Q2 		$160K Sell
32,247
-144,126
-82% -$780K ﹤0.01% 2659
2023
Q1 		$871K Buy
176,373
+51,985
+42% +$333K ﹤0.01% 1732
2022
Q4 		$782K Hold
124,388
– – ﹤0.01% 1772
2022
Q3 		$1.34M Buy
124,388
+94,369
+314% +$1.28M ﹤0.01% 1481
2022
Q2 		$342K Buy
30,019
+3,409
+13% +$30.3K ﹤0.01% 2081
2022
Q1 		$242K Hold
26,610
– – ﹤0.01% 2273
2021
Q4 		$397K Buy
26,610
+19
+0.1% +$335 ﹤0.01% 2140
2021
Q3 		$683K Hold
26,591
– – ﹤0.01% 1840
2021
Q2 		$693K Buy
26,591
+2,885
+12% +$82.3K ﹤0.01% 1893
2021
Q1 		$837K Buy
23,706
+276
+1% +$9.31K ﹤0.01% 1708
2020
Q4 		$591K Buy
23,430
+5,904
+34% +$192K ﹤0.01% 1809
2020
Q3 		$661K Buy
17,526
+893
+5% +$33.7K ﹤0.01% 1506
2020
Q2 		$712K Sell
16,633
-2,953
-15% -$107K ﹤0.01% 1437
2020
Q1 		$381K Buy
19,586
+682
+4% +$16.2K ﹤0.01% 1790
2019
Q4 		$491K Buy
18,904
+4,256
+29% +$117K ﹤0.01% 1899
2019
Q3 		$399K Hold
14,648
– – ﹤0.01% 1891
2019
Q2 		$393K Buy
14,648
+6,043
+70% +$168K ﹤0.01% 1935
2019
Q1 		$249K Hold
8,605
– – ﹤0.01% 2150
2018
Q4 		$232K Buy
+8,605
New +$229K ﹤0.01% 2161

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VOYA Investment Management's ALLO Position: Q1 2026 in Review

VOYA Investment Management reduced its Allogene Therapeutics (ALLO) stake by 3.3% in Q1 2026, selling an estimated $1.76K and leaving 25,976 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2252.

VOYA Investment Management first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.34M in Q3 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • VOYA Investment Management held 25,976 shares of Allogene Therapeutics worth $63.4K as of Q1 2026.
  • VOYA Investment Management sold 876 Allogene Therapeutics shares in Q1 2026, an estimated $1.76K.
  • Allogene Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q1 2026, its #2252 holding.
  • VOYA Investment Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • VOYA Investment Management's Allogene Therapeutics position peaked at $1.34M in Q3 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.